MARKET

SVRA

SVRA

Savara Inc
NASDAQ
4.640
-0.080
-1.69%
After Hours: 4.689 +0.049 +1.05% 16:31 11/13 EST
OPEN
4.800
PREV CLOSE
4.720
HIGH
4.845
LOW
4.580
VOLUME
3.23M
TURNOVER
--
52 WEEK HIGH
7.01
52 WEEK LOW
3.945
MARKET CAP
1.02B
P/E (TTM)
-7.6203
1D
5D
1M
3M
1Y
5Y
1D
Savara Stock Gets A Reality Check After Wider Quarterly Losses
Simply Wall St · 20h ago
Savara Announces New Employment Inducement Grant
Barchart · 1d ago
Savara Coverage Assumed by HC Wainwright & Co. at Buy
Dow Jones · 1d ago
Savara Price Target Announced at $10.00/Share by HC Wainwright & Co.
Dow Jones · 1d ago
SVRA's Quarterly Loss Matters Less Than What the FDA Decides Twelve Days Later
Barchart · 3d ago
Weekly Report: what happened at SVRA last week (1102-1106)?
Weekly Report · 4d ago
Savara (SVRA) Jumps 10% But Does Its 8.5x P B Still Look Pricey?
Simply Wall St · 6d ago
Big Pharma Has $1.2 Trillion to Spend and a Revenue Gap to Fill: Inside the F/m Emerald Life Sciences Innovation ETF (LFSC)
TipRanks · 11/02 12:00
More
About SVRA
Savara Inc. is a clinical-stage biopharmaceutical company. The Company is focused on rare respiratory diseases. The Company's lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The Company is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.

Webull offers Savara Inc stock information, including NASDAQ: SVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SVRA stock methods without spending real money on the virtual paper trading platform.